Profile
Catherine Gagnon is currently a Director at Katana Biopharma, Inc. She was previously a Director at Ovensa, Inc. and Head of Business Development at Angiochem, Inc. She received a graduate degree from the University of Montréal in 2000.
Former positions of Catherine Gagnon
| Companies | Position | End |
|---|---|---|
Katana Biopharma, Inc.
 Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Director/Board Member | - |
Ovensa, Inc.
 Ovensa, Inc. Internet Software/ServicesTechnology Services Ovensa, Inc. operates as a preclinical stage biotechnology company. It focuses in oncology and neurodegenerative diseases. The company is headquartered in Aurora, Canada. | Director/Board Member | - |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
Training of Catherine Gagnon
| University of Montréal | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Ovensa, Inc.
Ovensa, Inc. Internet Software/ServicesTechnology Services Ovensa, Inc. operates as a preclinical stage biotechnology company. It focuses in oncology and neurodegenerative diseases. The company is headquartered in Aurora, Canada. | Technology Services |
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Health Services |
- Stock Market
- Insiders
- Catherine Gagnon
